In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression

被引:100
作者
Hanauske, Axel-Rainer
Eismann, Ulrike
Oberschmidt, Olaf
Pospisil, Heike
Hoffmann, Steve
Hanauske-Abel, Hartmut
Ma, Doreen
Chen, Victor
Paoletti, Paolo
Niyikiza, Clet
机构
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] UMDNJ New Jersey Med Sch, Newark, NJ 07103 USA
[3] Univ Hamburg, Zentrum Bioinformat, D-20146 Hamburg, Germany
[4] Asklepios Klin, D-20099 Hamburg, Germany
关键词
pemetrexed disodium; gene expression; freshly explanted human tumors; thymidilate synthase; dihydrofolate reductase; glycinamide ribonucleotide formyltransferase; Mrp4; Mrp5; predictive testing;
D O I
10.1007/s10637-007-9060-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
mRNA expression of genes involved in the mechanism of action of pemetrexed was correlated with in vitro chemosensitivity of freshly explanted human tumor specimens.Chemosensitivity to pemetrexed was studied in soft-agar. Multiplex rtPCR experiments for reduced folate carrier (RFC), folate receptor-alpha (FR-alpha), folylpolyglutamate synthetase (FPGS), thymidylate synthase (TS), dihydrofolate reductase (DHFR), glycinamide ribonucleotide formyl transferase (GARFT), mrp4, and mrp5 were performed in parallel. Correlations, threshold optimization, sensitivity, specificity, and efficiency were analyzed using the appropriate statistical methodologies.In 61 samples, low levels of TS, GARFT, DHFR, and mrp4 gene expression significantly correlated with chemosensitivity to pemetrexed. Optimization analyses demonstrated threshold values of 144 copies for TS and six copies for mrp4 relative to 10(4) copies of beta-actin.These results form a rational basis for the design of clinical trials to evaluate the expression of these enzymes as predictors for treatment outcome.
引用
收藏
页码:417 / 423
页数:7
相关论文
共 29 条
  • [1] [Anonymous], R Project for Statistical Computing (Version 3.0.2)
  • [2] Ardalan B., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P201
  • [3] Bathe OF, 1999, CANCER J SCI AM, V5, P34
  • [4] Cascinu S, 1999, CLIN CANCER RES, V5, P1996
  • [5] Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells
    Giovannetti, E
    Mey, V
    Nannizzi, S
    Pasqualetti, G
    Marini, L
    Del Tacca, M
    Danesi, R
    [J]. MOLECULAR PHARMACOLOGY, 2005, 68 (01) : 110 - 118
  • [6] A phase II trial of pemetrexed in advanced breast cancer: Clinical response and association with molecular target expression
    Gomez, HL
    Santillana, SL
    Vallejos, CS
    Velarde, R
    Sanchez, J
    Wang, XP
    Bauer, NL
    Hockett, RD
    Chen, VJ
    Niyikiza, C
    Hanauske, AR
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (03) : 832 - 838
  • [7] HABECK LL, 1995, MOL PHARMACOL, V48, P326
  • [8] Hanauske AR, 2004, CANC DRUG DISC DEV, P63
  • [9] The role of Alimta in the treatment of malignant pleural mesothelioma: an overview of preclinical and clinical trials
    Hanauske, AR
    [J]. LUNG CANCER, 2004, 45 : S121 - S124
  • [10] Hanauske Axel R, 2004, Oncology (Williston Park), V18, P18